- Home
- AVIR vs CRDF Comparison
AVIR vs CRDF Comparison
Compare AVIR & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- CRDF
- Stock Information
- Founded
- AVIR 2012
- CRDF 1999
- Country
- AVIR United States
- CRDF United States
- Employees
- AVIR N/A
- CRDF N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AVIR Health Care
- CRDF Health Care
- Exchange
- AVIR Nasdaq
- CRDF Nasdaq
- Market Cap
- AVIR 273.7M
- CRDF 288.7M
- IPO Year
- AVIR 2020
- CRDF N/A
- Fundamental
- Price
- AVIR $2.85
- CRDF $3.06
- Analyst Decision
- AVIR Hold
- CRDF Strong Buy
- Analyst Count
- AVIR 1
- CRDF 4
- Target Price
- AVIR $6.88
- CRDF $12.00
- AVG Volume (30 Days)
- AVIR 247.5K
- CRDF 1.1M
- Earning Date
- AVIR 03-06-2025
- CRDF 05-01-2025
- Dividend Yield
- AVIR N/A
- CRDF N/A
- EPS Growth
- AVIR N/A
- CRDF N/A
- EPS
- AVIR N/A
- CRDF N/A
- Revenue
- AVIR N/A
- CRDF $683,000.00
- Revenue This Year
- AVIR N/A
- CRDF N/A
- Revenue Next Year
- AVIR N/A
- CRDF N/A
- P/E Ratio
- AVIR N/A
- CRDF N/A
- Revenue Growth
- AVIR N/A
- CRDF 39.96
- 52 Week Low
- AVIR $2.75
- CRDF $2.01
- 52 Week High
- AVIR $4.15
- CRDF $6.38
- Technical
- Relative Strength Index (RSI)
- AVIR 36.06
- CRDF 32.85
- Support Level
- AVIR $2.90
- CRDF $3.65
- Resistance Level
- AVIR $3.29
- CRDF $3.88
- Average True Range (ATR)
- AVIR 0.12
- CRDF 0.21
- MACD
- AVIR -0.03
- CRDF -0.08
- Stochastic Oscillator
- AVIR 8.33
- CRDF 9.30
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").